Targeting CDK4/6 in Patients With Cancer

Cancer Treatment Reviews - United Kingdom
doi 10.1016/j.ctrv.2016.03.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Inhibitors Targeting CDK4/6, PARP and PI3K in Breast Cancer: A Review

Therapeutic Advances in Medical Oncology
Oncology
2018English

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

CDK4/6 Inhibitors: Promising Opportunities Beyond Breast Cancer

Cancer Discovery
Oncology
2016English

CDK4/6 Inhibition in Cancer: The Cell Cycle Splicing Connection

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2019English

Therapeutic Targeting of the Cyclin D3:cdk4/6 Complex in T Cell Leukemia

Cancer Cell
Cancer ResearchOncologyCell Biology
2012English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Correction: CDK4/6 Inhibitors in the Treatment of Patients With Breast Cancer: Summary of a Multidisciplinary Round-Table Discussion

ESMO Open
Cancer ResearchOncology
2019English

Novel Germline CDK4 Mutations in Patients With Head and Neck Cancer

Hereditary Cancer in Clinical Practice
OncologyGenetics
2012English

CDK4/6 Inhibition Stabilizes Disease in Patients With P16-Null Non-Small Cell Lung Cancer and Is Synergistic With mTOR Inhibition

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy